ADAM MITCHELL: Open Payments
NPI 1881298727 · LOUISVILLE, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$941 in 36 payments from 11 companies in 2025. Trend: 2023 $1,780 · 2024 $1,355 · 2025 $941
Food & beverage: $941
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $219 |
| Vanda Pharmaceuticals Inc. | 5 | $124 |
| E.R. Squibb & Sons, L.L.C. | 6 | $116 |
| Otsuka America Pharmaceutical, Inc. | 5 | $109 |
| ABBVIE INC. | 1 | $103 |
| Alkermes, Inc. | 4 | $95 |
| Janssen Pharmaceuticals, Inc | 3 | $78 |
| Teva Pharmaceuticals USA, Inc. | 2 | $42 |
| Axsome Therapeutics, Inc. | 1 | $26 |
| Neurocrine BioSciences, Inc. | 1 | $15 |
Products named: CAPLYTA, COBENFY, VRAYLAR, HETLIOZ, INVEGA SUSTENNA, ARISTADA, ABILIFY MAINTENA, AUSTEDO XR.
Industry payments across KY — which companies pay providers there.
